Lilly to Seek FDA Approval for New Drug for Alzheimer Disease
Donanemab has already received a 'breakthrough therapy' designation from the FDA
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Donanemab has already received a 'breakthrough therapy' designation from the FDA
Only registered members have full access to PracticeUpdate content.